Skip to main content
. 2012 Nov;23(11):1797–1809. doi: 10.1681/ASN.2012020126

Figure 5.

Figure 5.

Oral administration of CRTH2 antagonist, CAY10471, attenuated the progression of tubulointerstitial fibrosis. (A) Representative images of Azan staining. The number of mice in the sham, preconditioning (CAY-10471 administration was started at 4 days before UUO), and day 3 administration and day 5 administration (CAY-10471 administration was started at 3 or 5 days after UUO, respectively) groups was 3, 6, 5, and 5, respectively. (B) Quantitative assessment of the fibrotic area. Data are the mean ± SD. ‡P<0.05 versus MC-fed; ∫P<0.001 versus sham of MC-fed; πP<0.01 versus sham of CAY10471; ∫∫P<0.05 versus UUO with preconditioning and day 3 administration of CAY10471 (two-sided t test, respectively). (C) Quantitative assessment of the collagen I-positive area. Data are the mean ± SD. ‡P<0.05 versus MC-fed; ∫P<0.001 versus sham of MC-fed; πP<0.01 versus sham of CAY10471; ∫∫P<0.05 versus UUO with preconditioning and day 3 administration of CAY10471 (two-sided t test, respectively). (D) Collagen I staining of paraffin sections. Representative images are shown. (E and F) Either the CRTH2 mRNA (E) or IL-4/IL-13 mRNA (F) expression was significantly increased at 3 days after UUO in CD45-positive fractions, but not in CD45-negative fractions (n=4 for each assay, ΣP<0.05 versus negative fraction).